China Resources Pharmaceutical | Sustainability Performance

https://www.crpharm.com/EN/

Engages in the research, manufacturing, and distribution of pharmaceutical products across therapeutic areas. It provides medicines and health solutions through retail and hospital channels, supported by domestic and international partnerships.

2007

China

10,001+ employees

Pharmaceuticals

$10B+ in revenue

$500M - 1B in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#6302

Overall

#113

in China

#131

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

103 out of 311

Overview

Environmental

Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversityClimate risk

Social

Diversity and InclusionPay GapsHealth and SafetyExternalities

Governance

TargetsSDG ImpactESG scores and Exclusions

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Beijing Tong RenTang

China, Health Care, Pharmaceuticals

Sinopharm

China, Health Care, Pharmaceuticals

Shanghai Pharmaceuticals

China, Health Care, Pharmaceuticals

Waste generated

183.6K tonnes, 2024

Laggard

Female employees

49% 2024

Aligned

Externalities

121.8M $, 2024

Critical

Market cap

25.6B $, 2026▲14.1% YoY

Revenue

257.7B $, 2024▼5% YoY

R&D intensity

0.78% 2024

Intensity

Energy consumption (direct) intensity (MWh /$M)

Industry Benchmark

31.2

B/M 35.5

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

China Resources Pharmaceutical Group Limited (CR Pharmaceutical, China Resources statecontrolled), Hong Konglisted Chinese major pharma, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of Chinese pharma customer compliance practices, plus periodic class actions over alleged inadequate disclosure of Chinese stateaffiliated controlling shareholder governance complexity affecting Hong Konglisted institutional minority shareholders amid Chinese statecontrolled pharma sector regulatory pressure.

KPI	Metric	Year
	2020	2021	2022	2023	2024	Benchmark
*******	*******	-	*******	*******	*******	*******	*******

Energy consumption breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Waste management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******

Air pollution

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	-	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	-	*******
*******	*******	*******	*******	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******

KPI	Metric	Year
	2013	2014	2015	2016	2017	Benchmark
*******	*******	-	-	-	-	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

China Resources Pharmaceutical Group Limited (CR Pharmaceutical, China Resources statecontrolled), Hong Konglisted Chinese major pharma, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of Chinese pharma customer compliance practices, plus periodic class actions over alleged inadequate disclosure of Chinese stateaffiliated controlling shareholder governance complexity affecting Hong Konglisted institutional minority shareholders amid Chinese statecontrolled pharma sector regulatory pressure.

China Resources Pharmaceutical | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable energy

Renewable electricity

Intensity

Female employees

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

Overall score

Environment

Social

Governance

Exclusion screening

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

China Resources Pharmaceutical | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable energy

Renewable electricity

Intensity

Female employees

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

Overall score

Environment

Social

Governance

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package